MindBio Reports Promising Phase 2A Results for Depression Treatment with LSD | Psychedelic Invest
MindBio Therapeutics Corp. (CSE) has recently unveiled promising durability data from its Phase 2A clinical trials, which tested MB22001, the company’s innovative self-administered, take-home microdose